References
- Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Toxicol Management Rev 1989;4:303–23.
- Lambert JR. Pharmacology of bismuth-containing compounds. Rev Infect Dis 1991;13:S691–5.
- Gorbach SL. Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990;99(3):863–75.
- Marshall B, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984. p. 1311–5.
- Veldhuyzen van Zanten SJ, Sherman PM. Indications for treatment of Helicobacter pylori infection: a systematic overview. Can Med Assoc J 1994;150:189–98.
- Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983. p. 1273–5.
- Peitz U, Menegatti M, Vaira D, Malfertheiner P. The European meeting on Helicobacter pylori: therapeutic news from Lisbon. Gut 1998;43 Suppl 1:S66–9.
- Hopkins RJ. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Gastroenterology 1997; 113 Suppl 6:S126–30.
- McNulty CAM, Dent J, Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother 1985;28: 837–8.
- Manhart MD. In vitro antibacterial of bismuth subsalicylate and other bismuth salts. Rev Infect Dis 1990;12 Suppl 1:S11–5.
- Courdon PE, Stratton CW. Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media. J Clin Microbiol 1995;33:1028–30.
- Stratton CW, Warner RR, Courdon PE, Lilly NA. Bismuth- mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J Antimicrob Chemother 1999;43:659–66.
- Rokkas T, Sladen GE. Bismuth: effects on gastritis and peptic ulcer. Scand J Gastroenterol 1988;23 Suppl 142:82–6.
- Gregory MA, Moshal MG, Spitaels JM. The effect of tripotassium di-citrato bismuthate on the duodenal mucosa during ulceration. An ultrastructural study. S Afr Med J 1982;62:52–5.
- Ottlecz A, Romero JJ, Lichtenberger LM. Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical study. Aliment Pharmacol Ther 1999;13: 875–81.
- Wagner S, Beil W, Mai UE, Bokemeyer C, Meyer HJ. Interaction between Helicobacter pylori and human gastric epithelial cells in culture: effect of antiulcer drugs. Pharmacology 1994;49: 226–37.
- Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 1987;37 Suppl 2:16–30.
- Worku ML, Sidebotham RL, Karim QN. Effects of ranitidine bismuth citrate on Helicobacter pylori motility, morphology and survival. Aliment Pharmacol Ther 1999;13: 753–60.
- Armstrong JA, Wee SH, Goodwin CS, Wilson DH. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid- reducing agent in vitro-an ultrastructural study. J Med Microbiol 1987;24:343–50.
- Ross JF, Switzer RC, Poston MR, Lawhorn GT. Distribution of bismuth in the brain after intraperitoneal dosing of bismuth subnitrate in mice: implications for routes of entry of xenobiotic metals into the brain. Brain Res 1996;725:137–54.
- Danscher G, Stoltenberg M, Kemp K, Pamphlett R. Bismuth autometallography. Protocol, specificity, and differentiation. J Histochem Cytochem 2000;48:1503–10.
- Martin-Bouyer G, Foulon B, Guerbois H, Barin C. Aspects epidemiologiques des encéphalopathies après administration de bismuth par voie orale. Therapie 1980;35:307–13.
- Martin-Bouyer G, Foulon G, Guerbois H, Barin C. Epidemiological study of encephalopathies following bismuth administration per Os. Characteristics of intoxicated subjects: comparison with a control group. Clin Toxicol 1981;18: 1277–83.
- Locke M, Nichol H, Ketola-Pirie C. Binding of bismuth to cell components: clue to mode of action and side effects. Can Med Assoc J 1987;137:991–2.